Pantherna Therapeutics is a privately held mRNA therapeutics company developing novel first-in-class therapies for indications with high unmet medical need. Pantherna’s development programs are based on two innovative and proprietary PTX platform technologies, offering robust mRNA expression constructs (PTX-mRNA) and lipid nanoparticle (LNP) delivery vehicles (PTX-LNP) for localized expression of therapeutic proteins. PAN004 is Pantherna’s first development candidate derived from this platform, representing a defined mRNA-LNP formulation for selective mRNA delivery and expression of a Tie2-agonist in the vascular endothelium of the lung. Pantherna strives for expanding its pipeline with various novel mRNA-LNP candidates enabling the therapeutic use of mRNA beyond the vascular endothelium in distinct tissues such as skeletal muscle or immune cells.
Something looks off?Portfolio Jobs
Browse through our portfolio jobs and select a suitable opportunity.
0
COMPANIES
0
JOBS